CompletedPhase 1NCT01881984
Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation
Studying Acyl-CoA dehydrogenase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Pittsburgh
- Principal Investigator
- Gerard Vockley, MD, PhDUniversity of Pittsburgh/Children's Hospital of Pittsburgh of UPMC
- Intervention
- Ravicti(drug)
- Enrollment
- 4 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2016
Study locations (1)
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Collaborators
Horizon Pharma Ireland, Ltd., Dublin Ireland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01881984 on ClinicalTrials.govOther trials for Acyl-CoA dehydrogenase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07097311Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)Jerry Vockley, MD, PhD
- RECRUITINGPHASE2NCT06773026Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)Jerry Vockley, MD, PhD
- RECRUITINGNANCT06623032Metabolic Effects of Medium-Chain Fatty Acids in Patients With Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Healthy IndividualsUniversity of Copenhagen